BioMarin Pharmaceutical Inc
BMRN
View Detailed Chart
58.130USD
+0.980+1.71%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
11.17BMarket Cap
21.38P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.71%
5 Days
+2.81%
1 Month
-3.23%
6 Months
-4.19%
Year to Date
-2.19%
1 Year
-9.65%
View Detailed Chart
TradingKey Stock Score of BioMarin Pharmaceutical Inc
Currency: USD Updated: 2026-02-06Key Insights
BioMarin Pharmaceutical Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 43 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 90.89.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioMarin Pharmaceutical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BioMarin Pharmaceutical Inc Highlights
StrengthsRisks
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 36.16% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.85B.
Undervalued
The company’s latest PE is 21.38, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 187.90M shares, increasing 0.04% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 17.35K shares of this stock.
Analyst Rating
Based on
26
analysts
Buy
Current Rating
90.889
Target Price
+59.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioMarin Pharmaceutical Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioMarin Pharmaceutical Inc Info
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Ticker SymbolBMRN
CompanyBioMarin Pharmaceutical Inc
CEOHardy (Alexander)
Websitehttps://www.biomarin.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68979.090
-991.040 (-1.42%)
282.580
+22.390 (+8.61%)
2062.700
+10.970 (+0.53%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
